Search Results - "López Garrido, P"

Primary congenital glaucoma caused by the homozygous F261L CYP1B1 mutation and paternal isodisomy of chromosome 2 by López-Garrido, M-P, Campos-Mollo, E, Harto, M-Á, Escribano, J

“…Primary congenital glaucoma (PCG), a rare, severe and blinding disease, usually results from mutations in the CYP1B1 gene located in chromosome 2p22.2…”
Get full text

Functional analysis of CYP1B1 mutations and association of heterozygous hypomorphic alleles with primary open-angle glaucoma by López-Garrido, M-P, Blanco-Marchite, C, Sánchez-Sánchez, F, López-Sánchez, E, Chaqués-Alepuz, V, Campos-Mollo, E, Salinas-Sánchez, AS, Escribano, J

“…López‐Garrido M‐P, Blanco‐Marchite C, Sánchez‐Sánchez F, López‐Sánchez E, Chaqués‐Alepuz V, Campos‐Mollo E, Salinas‐Sánchez AS, Escribano J. Functional…”
Get full text

Co-inheritance of HNF1a and GCK mutations in a family with maturity-onset diabetes of the young (MODY): implications for genetic testing by López-Garrido, M. P., Herranz-Antolín, S., Alija-Merillas, M. J., Giralt, P., Escribano, J.

“…Summary Objective To determine the genetic basis of dominant early‐onset diabetes mellitus in two families. Patients and methods Molecular analysis by PCR…”
Get full text

European Society of Cardiology quality indicators for the prevention and management of cancer therapy-related cardiovascular toxicity in cancer treatment by Lee, G A, Aktaa, S, Baker, E, Gale, C P, Yaseen, Israa F, Gulati, G, Asteggiano, R, Szmit, S, Cohen-Solal, A, Abdin, A, Jurczak, W, Garrido Lopez, P, Sverdlov, A L, Tocchetti, C G, Barac, A, Parrini, I, Zamorano, P, Iakobishvili, Z, Pudil, R, Badimon, L, Kirby, A M, Blaes, A H, Farmakis, D, Curigliano, G, Stephens, R, Lyon, A R, Lopez-Fernandez, T

“…Abstract Aims To develop quality indicators (QIs) for the evaluation of the prevention and management of cancer therapy-related cardiovascular toxicity…”
Get full text

Sarcoidosis-like reactions in cancer patients treated with immune checkpoint inhibitors: experience in a Spanish hospital by Torres-Jiménez, J., Esteban-Villarrubia, J., García-Abellás, P., Cortés-Salgado, A., Soria-Rivas, A., Gajate-Borau, P., Olmedo-García, M. E., Corral-de la Fuente, E., Lage-Alfranca, Y., Gómez-Rueda, A., Benito-Berlinches, A., Gorospe-Sarasua, L., Garrido-López, P.

“…Background Immune checkpoint inhibitors (ICI) have been associated with several immune-related adverse events, including sarcoidosis-like reactions (SLR). SLR,…”
Get full text

A call for hope by Garrido López, P, Gorospe Sarasúa, L

Get full text

PACIFIC-R: First real-world study of patients with unresectable, stage III NSCLC treated with durvalumab after chemoradiotherapy by Girard, N., Mornex, F., Christoph, D.C., Fietkau, R., Filippi, A.R., Field, J., Garrido Lopez, P., McDonald, F., Peters, S., Klein, A.B., Licour, M., Garassino, M.C.

Get full text

An open-label, randomized, phase I/II trial of IO102 and pembrolizumab, or IO102, pembrolizumab and chemotherapy, as first-line treatment for patients with metastatic non-small cell lung cancer by Spicer, J., Provencio, M., Garrido Lopez, P., Bosch-Barrera, J., de Castro Carpeño, F.J., Felip, E., Trigo, J., Viteri, S., Coart, E., Schmidt, E., Christiansen, A.V., Zocca, M.-B., Andersen, M.H., Ehrnrooth, E., Paz-Ares, L.

Get full text

Phase I/II study of spartalizumab (PDR001), an anti-PD1 mAb, in patients with advanced melanoma or non-small cell lung cancer by Lin, C.-C., Taylor, M., Boni, V., Brunsvig, P.F., Geater, S.L., Salvagni, S., Garrido Lopez, P., Özgüroğlu, M., Sriuranpong, V., Ponce Aix, S., Ascierto, P.A., Fasolo, A., Sezer, A., Kowalski, D.M., Faris, J.E., Cameron, S., Mataraza, J., Wu, H., Antona, V., Ochoa de Olza, M.

Get full text

The role of scientific societies in a post-COVID world by García-Alegría, J., Garrido-López, P., Abarca Buján, Benjamín, Íñiguez Romo, Andrés, Avendaño Solá, Cristina, Cubero González, Paulino, Fernández Ruiz, Juan Sergio, Gayete Cara, Ángel, Hernández Rivas, José Ángel, Jover Javalón, José María, Santander Vaquero, Cecilio

Get full text

Phase I expansion cohort results of cemiplimab, a human PD-1 monoclonal antibody, in combination with radiotherapy (RT), cyclophosphamide and GM-CSF, in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) by Babiker, H.M., Brana, I., Mahadevan, D., Owonikoko, T.K., Calvo, E., Rischin, D., Moreno, V., Papadopoulos, K.P., Crittenden, M., Formenti, S., Giralt, J., Garrido Lopez, P., Hervás Morón, A., Mohan, K.K., Fury, M.G., Lowy, I., Stankevich, E., Feng, M., Li, J., Mathias, M.

Get full text

Cemiplimab, a human monoclonal anti-PD-1, plus radiotherapy (RT) in advanced non-small cell lung cancer (NSCLC): Results from a phase I expansion cohort (EC 2) by Moreno, V., Gil-Martin, M., Johnson, M., Aljumaily, R., Lopez Criado, P., Northfelt, D.W., Crittenden, M., Jabbour, S., Rosen, L., Garrido Lopez, P., Hervás Morón, A., Rietschel, P., Mohan, K.K., Li, J., Stankevich, E., Rowlands, T., Feng, M., Lowy, I., Fury, M.G.

Get full text

LungBEAM: A prospective multicenter trial to monitor EGFR mutations using BEAMing technology in stage IV NSCLC patients by Garrido Lopez, P., Felip, E., Paz-Ares, L., Majem, M., Moran, T., Gonzalez-Larriba, J.L., Bosch Barrera, J., Trigo Perez, J.M., Garcia Campelo, M.R., Sanchez Torres, J.M., Isla, D., Vinolas Segarra, N., Camps, C., Insa Molla, A., Juan Vidal, O.J., Massutí, B., Paredes Lario, A., Artal-Cortes, A., Lopez-Brea Piqueras, M., Palacios Calvo, J.

Get full text

A call for hope by Garrido López, P, Gorospe Sarasúa, L

Get more information

A call for hope by Garrido López, P., Gorospe Sarasúa, L.

Get full text

Diabetes de comienzo en la infancia tratada con sulfonilureas by Palomo Atance, E, Ballester Herrera, M.J, Giralt Muiña, P, López Garrido, P

“…La diabetes MODY ( maturity onset diabetes of the young ) tipo 3 pertenece al grupo de las diabetes monogénicas y está causada por mutaciones en los genes del…”
Get full text

PB2267 PERCEPTION OF THE DISCONTINUATION OF TYROSINE‐KINASE INHIBITOR TREATMENT IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA OF THE ANDALUSIAN GROUP OF CML (GALMC) by Fernandez, E. L.ó.pez, Puerta, J. M. Puerta, Badiola, J., Marfil, M.N. P.é.rez, Chaves, C. Ferrer, Pérez, M. J. García, Molina, C. Avellaneda, Arance, M. Anguita, Garrido, P. López, Fernández, S. De Linares

“…Background: The encouraging results of the first clinical trials evaluating the discontinuation of tyrosine‐kinase inhibitor (TKI) treatment in patients with…”
Get full text

PB1945 EXPERIENCE OF THE ANDALUSIAN CHRONIC MYELOID LEUKEMIA GROUP (GALMC) IN THE DISCONTINUATION OF THE TYROSINE KINASE INHIBITOR TREATMENT OUTSIDE OF CLINICAL TRIALS by Alarcón‐Payer, C., Puerta Puerta, J.M., Jiménez Morales, A., Ramírez Sánchez, M.J., Montero Cuadrado, M.I., Mata Vázquez, M.I., Ferrer Chaves, C., Anguita Arance, M., Vera Goñi, J.A., García Pérez, M.J., Mellado Gázquez, Á., Moatassim de la Torre, Y., Hermosín Ramos, L., Jurado Chacón, M., López Garrido, P.

“…Background: Currently one of the most burning issues regarding the specific treatment of Chronic Myeloid Leukemia (CML) with Interleukin‐2‐inducible T‐cell…”
Get full text

110P Characteristics and survival outcomes of patients (pts) with RET fusion-positive (RET-fp) solid tumours receiving non-RET inhibitor (RETi) therapy in a real-world setting by Garrido Lopez, P., Siena, S., Taylor, M., Beringer, A., Bordogna, W., Fajardo, O., Nikolaidis, C.

Get full text

490MO Patient-reported outcomes of first-line selpercatinib versus chemotherapy with or without pembrolizumab in RET fusion-positive advanced non-small cell lung cancer: Interim analysis of LIBRETTO-431 by Goto, K., Novello, S., Garrido Lopez, P., Dooms, C., Alatorre Alexander, J.A., Reinmuth, N., Gilligan, A., Payakachat, N., Lin, A., Cocks, K., Worthy, G., Zhou, C.

Get full text